Ref: NEPHROPLUS/SE/85

September 18, 2026

To
BSE Limited
P.J. Towers, Dalal Street,
Mumbai – 400 001
Scrip Code: 544647
Through: BSE Listing Centre

To
National Stock Exchange of India Limited
5th Floor, Exchange Plaza, Bandra (E),
Mumbai – 400 051
Scrip Symbol: NEPHROPLUS
Through: NEAPS

Subject: Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 - Rationalisation and Consolidation of the Company's Step-down Subsidiaries in the Philippines

Dear Sir/Madam,

Pursuant to Regulation 30 read with Para A of Part A of Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("**SEBI Listing Regulations**"), we hereby inform that the Board of Directors of Nephrocare Health Services Limited ("**Company**"), at its meeting held today, i.e., Friday, September 18, 2026, has approved the proposed rationalisation and consolidation of the Company's step-down subsidiaries in the Philippines, subject to compliance with applicable laws and receipt of such statutory, regulatory, corporate and other approvals as may be required.

The proposed rationalisation and consolidation is intended to simplify the existing structure of the Group's Philippine operations, thereby improving operational, administrative and cost efficiencies and strengthening management and governance oversight. This simplified structure will, in turn, be more scalable and better aligned with the Company's international growth strategy.

The details as required under Regulation 30 of the SEBI Listing Regulations read with the applicable SEBI Master Circular Ref. No. HO/49/14/14(7)2025-CFDPOD2/ I/3762/2026 dated January 30, 2026 are enclosed herewith as **Annexure A**.

The Company shall make further disclosures/updates in relation to the proposed rationalisation and consolidation, as may be required under the SEBI Listing Regulations.

The meeting of Board of Directors commenced at 03:20 p.m. IST and concluded at about 03:45 p.m. IST.

The above information is also being made available on the website of the Company at www.nephroplus.com.

Kindly take the above information on record.

Yours faithfully,
For **Nephrocare Health Services Limited**
(Formerly Nephrocare Health Services Private Limited)

Kathri Kishore
Digitally signed by Kathri Kishore
Date: 2026.09.18 16:08:40 +05'30'

Kishore Kathri
Company Secretary and Head Legal
Membership No.: F9895

Nephrocare Health Services Limited (Global Corporate Headquarters)
(Formerly Nephrocare Health Services Private Limited)
5th Floor, D Block, iLabs Centre, Plot: 18, Software Units Layout, Survey No: 64, Madhapur, Hyderabad - 500 081, Telangana, India.
+91 40 4240 8039 contactus@nephroplus.com www.nephroplus.com
CIN: L85100TG2009PLC066359 | GSTIN: 36AADCN1504A1Z8 | ISD GST: 36AADCN1504A2Z7

ANNEXURE A

Details pursuant to Regulation 30 read with Para A of Part A of Schedule III of the SEBI Listing Regulations

S. No.	Particulars	Details
1.	Details and reasons for restructuring	Nephrocare Health Care Services Philippines, Inc. ("**Nephrocare PH**"), a step-down subsidiary of the Company held through Nephrocare Health Services International Pte. Ltd., Singapore, operates the Group's business in the Philippines through multiple wholly-owned subsidiaries. As part of the Group's ongoing efforts to simplify its corporate structure and enhance operational efficiency, the Group proposes to rationalise and consolidate its existing Philippine subsidiary structure into a smaller number of operating entities. The proposed consolidation is expected to streamline administrative and compliance processes, optimise costs and strengthen management and governance oversight. The consolidation will be implemented in a phased manner, subject to applicable laws and receipt of requisite approvals in India and the Philippines.
2.	Quantitative and/or qualitative effect of restructuring	The proposed rationalisation and consolidation is an internal reorganisation of the Group's Philippine operations, aimed at simplifying the existing entity structure and enhancing operational, administrative and compliance efficiencies. The transaction will not involve any third-party investor or result in any change in the Company's ultimate economic interest or control over the Philippine operations. The transaction is proposed to be accounted for as a common-control transaction in accordance with the applicable accounting framework.
3.	Details of benefit, if any, to the promoter/promoter group/group companies from such proposed restructuring	The proposed rationalisation and consolidation is an internal reorganisation of the Group's existing Philippine operations and does not envisage any specific benefit to the promoter or promoter group of the Company.
4.	Brief details of change in shareholding pattern, if any, of all entities	There will be no change in the shareholding pattern of the Company or in the ultimate ownership and control of the Philippine business. Nephrocare PH will continue to remain a step-down subsidiary of the Company through Nephrocare Health Services International Pte. Ltd., Singapore. The proposed consolidation will result only in an internal reorganisation of the ownership structure among the Philippine entities, without any change in the Company's ultimate economic interest or control over the Philippine operations.

***